Literature DB >> 7627933

Cytogenetic findings in 200 patients with multiple myeloma.

J R Sawyer1, J A Waldron, S Jagannath, B Barlogie.   

Abstract

Cytogenetic studies were performed in 200 consecutive patients with multiple myeloma and related disorders. Structurally or numerically abnormal clones were found in 63 patients (32%), including 8 of 45 untreated patients (18%), and 55 of 155 treated patients (35%). The abnormal karyotypes generally showed numerous numerical and structural aberrations and in some patients multiple abnormal clones. The most striking feature of patients with hyperdiploid karyotypes was the finding of consistent recurring trisomies for chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, cosegregating together in many cases. Monosomy for chromosome 13 was the most common chromosome loss, occurring in 18 abnormal patients (29%), while interstitial deletions involving band 13q14 occurred in an additional 9 patients, indicating a loss of all or part of chromosome 13 in a high percentage of patients with abnormal karyotypes (43%). Structural aberrations of chromosome 1 were most frequent, occurring in 30 of 63 patients (48%), and involved almost equally the short and long arms. The single most frequent chromosome breakpoint involved band 14q32 and was found in 21 patients (33%), including 11 patients with a 14q+ chromosome, 8 with t(11;14)(q13;q32), and 2 with t(8;14)(q24;132).

Entities:  

Mesh:

Year:  1995        PMID: 7627933     DOI: 10.1016/0165-4608(94)00284-i

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  56 in total

1.  Prediction of cytogenetic abnormalities with gene expression profiles.

Authors:  Yiming Zhou; Qing Zhang; Owen Stephens; Christoph J Heuck; Erming Tian; Jeffrey R Sawyer; Marie-Astrid Cartron-Mizeracki; Pingping Qu; Jason Keller; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

2.  Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.

Authors:  Shanthi Sivendran; Stephen Gruenstein; Adriana K Malone; Vesna Najfeld
Journal:  J Hematol Oncol       Date:  2010-07-22       Impact factor: 17.388

3.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

4.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Authors:  Mauricio Pineda-Roman; Maurizio Zangari; Jeff Haessler; Elias Anaissie; Guido Tricot; Frits van Rhee; John Crowley; John D Shaughnessy; Bart Barlogie
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

5.  Suppression of abnormal karyotype predicts superior survival in multiple myeloma.

Authors:  V Arzoumanian; A Hoering; J Sawyer; F van Rhee; C Bailey; J Gurley; J D Shaughnessy; E Anaissie; J Crowley; B Barlogie
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

Review 6.  Genomics in multiple myeloma.

Authors:  Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

Review 7.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Dysfunctional homologous recombination mediates genomic instability and progression in myeloma.

Authors:  Masood A Shammas; Robert J Shmookler Reis; Hemanta Koley; Ramesh B Batchu; Cheng Li; Nikhil C Munshi
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

10.  Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Authors:  Scott Van Wier; Esteban Braggio; Angela Baker; Gregory Ahmann; Joan Levy; John D Carpten; Rafael Fonseca
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.